Pathological Analysis and Clinical Evolution After Radiological Removal of Retrievable Vena Cava Filters.


Journal

Vascular and endovascular surgery
ISSN: 1938-9116
Titre abrégé: Vasc Endovascular Surg
Pays: United States
ID NLM: 101136421

Informations de publication

Date de publication:
Nov 2022
Historique:
pubmed: 16 8 2022
medline: 19 10 2022
entrez: 15 8 2022
Statut: ppublish

Résumé

Retrievable inferior vena cava filters (IVCF) have been developed because permanent filters have been associated with an increased risk of recurrent deep venous thrombosis. There is no data on the interactions of IVCF with the inferior vena cava (intrafilter thrombi, insertion through the venous wall) even though this may alter the course after retrieval of the IVCF. A review of 85 consecutive patients undergoing retrieval of IVCF placed at a single center was performed from January 1, 2010 and December 31, 2014. Inferior vena cava filter were examined for presence of intrafilter thrombus at time of retrieval. Filter position and presence of intraluminal thrombus were examined. Patient outcomes, including recurrence of deep vein thrombosis (DVT) and death, were captured at 3 month followup. Eighty five patients were identified, with intrafilter thrombi found in 69 (81%) patients and venous wall fragments found in 75 (88%) patients. However, their presence was not associated with an increased risk of recurrent venous thromboembolism (VTE) or death during follow up. Intrafilter thrombi and venous wall fragments are frequently found in removed IVCF but are not associated with a worse prognosis. They may not modify the therapeutic management of patients.

Identifiants

pubmed: 35968824
doi: 10.1177/15385744221120764
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

754-761

Auteurs

Thierry Annweiler (T)

Service de Radiologie, 26926Centre Hospitalier Universitaire de St-Etienne, Saint-Etienne, France.

Laurent Bertoletti (L)

Service de Médecine Vasculaire et Thérapeutique, 26926Centre Hospitalier Universitaire de St-Etienne, Saint-Etienne, France.
INSERM, UMR1059, Equipe Dysfonction Vasculaire et Hémostase, Université Jean-Monnet, Saint-Etienne, France.
INSERM, CIC-1408, CHU Saint-Etienne, Saint-Etienne, France.

Sylvain Grange (S)

Service de Radiologie, 26926Centre Hospitalier Universitaire de St-Etienne, Saint-Etienne, France.

Michel Peoc'h (M)

Department of Pathology, 26926CHU de St-Etienne, Saint-Etienne, France.

Patrick Mismetti (P)

Service de Médecine Vasculaire et Thérapeutique, 26926Centre Hospitalier Universitaire de St-Etienne, Saint-Etienne, France.
INSERM, UMR1059, Equipe Dysfonction Vasculaire et Hémostase, Université Jean-Monnet, Saint-Etienne, France.
INSERM, CIC-1408, CHU Saint-Etienne, Saint-Etienne, France.

Fabrice-Guy Barral (FG)

Service de Radiologie, 26926Centre Hospitalier Universitaire de St-Etienne, Saint-Etienne, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH